FDA's Anticounterfeiting Guidance Dodges Secrecy Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
In final guidance on the use of physical-chemical identifiers in solid oral dosage form drugs, FDA avoids addressing commenters' qualms about confidentiality.